Bupropion and naltrexone for smoking cessation: A double‐blind randomized placebo‐controlled clinical trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Combination of non‐nicotine pharmacotherapies has been underexamined for cigarette smoking cessation. A randomized, double‐blind, parallel‐group double‐dummy study evaluated two medications, bupropion (BUP) and naltrexone (NTX), in treatment‐seeking cigarette smokers (N= 121) over a 7‐week treatment intervention with 6‐month follow‐up. Smokers were randomized to either BUP (300 mg/day) + placebo (PBO) or BUP (300 mg/day) + NTX (50 mg/day). The primary outcome was biochemically verified (saliva cotinine, carbon monoxide) 7‐day, point‐prevalence abstinence. BUP + NTX was associated with significantly higher point‐prevalence abstinence rates after 7‐weeks of treatment (BUP + NTX, 54.1%; BUP + PBO, 33.3%),P= 0.0210, but not at 6‐month follow‐up (BUP + NTX, 27.9%; BUP + PBO, 15.0%),P= 0.09. Continuous abstinence rates did not differ,P= 0.0740 (BUP + NTX, 26.2%; BUP + PBO, 13.3%). Those receiving BUP + NTX reported reduced nicotine withdrawal,P= 0.0364. The BUP + NTX combination was associated with elevated rates of some side effects, but with no significant difference in retention between the groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemical verification of tobacco use and cessation
Benowitz, N. L., III, P. J., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J., Hansson, A., Lichtenstein, E., Henningfield, J., Tsoh, J., et al. (2002) · Nicotine & Tobacco Research · doi:10.1080/14622200210123581 · Cited by 1,800
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“With the advent of non-nicotine pharmacotherapies (NNPs), such as bupropion and varenicline, CP research expanded to include NRT 1 NNP treatments.(5) Multiple trials have combined bupropion (BUP) and the nicotine patch.”
BackgroundAntidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188 · cited 2×
“Urges and cravings to smoke were assessed via the brief version of the Questionnaire of Smoking Urges.(45,46) The Questionnaire of Smoking Urges consists of two scales derived from factor analysis: factor 1 (smoking for positive reinforcement, anticipated pleasure from smoking), and factor 2 (smoking for negative rein…”
MethodThe development and initial validation of a questionnaire on smoking urges
TIFFANY, S. T., & DROBES, D. J. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01732.x · Cited by 974
Bupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Piasecki, T. M. (2006) · Clinical Psychology Review · doi:10.1016/j.cpr.2005.11.007 · Cited by 370 · cited 1×
“Nicotine withdrawal Nicotine withdrawal plays a critical role in relapse to cigarette smoking.(33) Nicotine withdrawal is generally worse in the initial weeks following cessation, after which most symptoms return to baseline levels.”
BackgroundThe effect of bupropion on nicotine craving and withdrawal
Shiffman, S., Johnston, J. A., Khayrallah, M., Elash, C. A., Gwaltney, C. J., Paty, J. A., Gnys, M., Evoniuk, G., & DeVeaugh-Geiss, J. (2000) · Psychopharmacology · doi:10.1007/s002130050022 · Cited by 259
Hall, S. M., Delucchi, K. L., Velicer, W. F., Kahler, C. W., Ranger-Moore, J., Hedeker, D., Tsoh, J. Y., & Niaura, R. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200110050411 · Cited by 188
Natural history of nicotine withdrawal
Shiffman, S., Patten, C., Gwaltney, C., Paty, J., Gnys, M., Kassel, J., Hickcox, M., Waters, A., & Balabanis, M. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01635.x · Cited by 104
Combination Pharmacotherapy for Stopping Smoking: What Advantages Does it Offer?
Ebbert, J. O., Hays, J. T., & Hurt, R. D. (2010) · Drugs · doi:10.2165/11536100-000000000-00000 · Cited by 53
Cited by
The dopamine motive system: implications for drug and food addiction
Volkow, N. D., Wise, R. A., & Baler, R. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.130 · Cited by 939
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
Le Foll, B., Piper, M. E., Fowler, C. D., Tonstad, S., Bierut, L., Lu, L., Jha, P., & Hall, W. D. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00346-w · Cited by 316
Horn, D. B., Almandoz, J. P., & Look, M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2051366 · Cited by 114
“If a patient is a smoker, naltrexone–bupropion could be considered as a first choice, since it may help the patient with smoking cessation [126].”
Background
Metadata
- Authors
- Mooney, M., Schmitz, J., Allen, S., Grabowski, J., Pentel, P., Oliver, A., & Hatsukami, D.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2016-06-20
- Volume
- 100
- Issue
- 4
- Pages
- 344-352
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2399413811
- Cited by
- 28
- References
- 12
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.